Ervahanine B






Names

    • Ervahanine B

Attributes

  • Canonical SMILES

    C/C=C1C2C[C@H](C3=C(C4=CC=CC=C4N3)CC(N(C/1)C)[C@@H]2C(OC)=O)C5=CC(C(CCN(C6)[C@@]7([H])[C@]8(C(OC)=O)C[C@]6([H])C[C@H]7CC)=C8N9)=C9C=C5

  • InChI

    InChI=1S/C42H50N4O4/c1-6-24-16-23-20-42(41(48)50-5)38-28(14-15-46(21-23)39(24)42)31-17-26(12-13-34(31)44-38)30-18-29-25(7-2)22-45(3)35(36(29)40(47)49-4)19-32-27-10-8-9-11-33(27)43-37(30)32/h7-13,17,23-24,29-30,35-36,39,43-44H,6,14-16,18-22H2,1-5H3/b25-7+/t23-,24+,29?,30-,35?,36+,39+,42-/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 90.66
  • #RotBonds: 4
  • MW: 674.8860000000001
  • HBD: 2
  • HBA: 6
  • logP: 6.480300000000007
  • Chemical Formula: C42H50N4O4


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. bufalina China 403123 Cai20170220

External Databases


References

  • Iboga-type alkaloids with Indolizidino[8,7-b]Indole scaffold and bisindole alkaloids from Tabernaemontana bufalina Lour. Phytochemistry, 2022 (PMID 35074605).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • α-glucosidase inhibitory
    • Antimicrobial
    • Butyrylcholinesterase

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.92
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney 3.75
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 1236.81
    Distribution Blood-Brain Barrier (Central Nervous System) -3.46
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.43
    Plasma Protein Binding 87.23
    Steady State Volume of Distribution 5.48
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Inhibitor
    Excretion Clearance 11.93
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -30.06
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.47
    Liver Injury II Safe
    hERG Blockers Toxic
    Daphnia Maga 6.12
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -2242978.29
    Rat (Acute) 2.88
    Rat (Chronic Oral) 2.21
    Fathead Minnow 2833.35
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 248958.11
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 5.37
    Log(P) 5.57
    Log S -5.79
    Log(Vapor Pressure) -8139.22
    Melting Point 282.88
    pKa Acid -26.32
    pKa Basic 5.95